NYSE:COV - Covidien Stock Price, Price Target & More

$106.71 0.00 (0.00 %)
(As of 04/23/2018 09:25 AM ET)
Previous Close$106.71
Today's RangeN/A
52-Week Range$65.97 - $108.57
Average Volume3.88 million shs
Market Capitalization$48.98 billion
P/E RatioN/A
Dividend Yield1.35%

About Covidien (NYSE:COV)

Covidien logoCovidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.

Receive COV News and Ratings via Email

Sign-up to receive the latest news and ratings for COV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins19.02%
Return on Equity20.06%
Return on Assets9.92%


Outstanding Shares454,510,000

How to Become a New Pot Stock Millionaire

Covidien (NYSE:COV) Frequently Asked Questions

What is Covidien's stock symbol?

Covidien trades on the New York Stock Exchange (NYSE) under the ticker symbol "COV."

How were Covidien's earnings last quarter?

Covidien Ltd (NYSE:COV) issued its quarterly earnings data on Wednesday, November, 5th. The healthcare company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.13. The healthcare company had revenue of $2.73 billion for the quarter, compared to analyst estimates of $2.69 billion. Covidien had a return on equity of 20.06% and a net margin of 19.02%. The company's revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.91 EPS. View Covidien's Earnings History.

Who are some of Covidien's key competitors?

Who are Covidien's key executives?

Covidien's management team includes the folowing people:
  • Gary L. Ellis, President, Chief Executive Officer (Age 61)
  • Charles J. Dockendorff, Chief Financial Officer, Executive Vice President (Age 63)
  • Bryan C. Hanson, Group President, Covidien (Age 50)
  • John H. Masterson, Senior Vice President, General Counsel (Age 54)
  • Michael P. Dunford, Senior Vice President - Human Resources (Age 54)
  • James C. Clemmer, Senior Vice President and President - Medical Supplies Business (Age 53)
  • Amy A. McBride-Wendell, Senior Vice President - Strategy and Business Development (Age 53)
  • Jacqueline F. Strayer, Senior Vice President-Corporate Communications (Age 58)
  • Michael E. Tarnoff, Senior Vice President,Chief Medical Officer (Age 46)
  • Peter L. Wehrly, Senior Vice President, Group President - Developed Markets (Age 57)

Has Covidien been receiving favorable news coverage?

News stories about COV stock have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Covidien earned a coverage optimism score of 0.14 on Accern's scale. They also assigned press coverage about the healthcare company an impact score of 47.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Covidien?

Shares of COV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Covidien's stock price today?

One share of COV stock can currently be purchased for approximately $106.71.

How big of a company is Covidien?

Covidien has a market capitalization of $48.98 billion.

How can I contact Covidien?

Covidien's mailing address is 20 On Hatch Lower Hatch Street, Dublin 2, DUBLIN,, Ireland. The healthcare company can be reached via phone at +353-1-4381700.

MarketBeat Community Rating for Covidien (COV)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  498
MarketBeat's community ratings are surveys of what our community members think about Covidien and other stocks. Vote "Outperform" if you believe COV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Covidien (NYSE:COV) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/23/2016 forward)


Covidien (NYSE:COV) Earnings History and Estimates Chart

Earnings by Quarter for Covidien (NYSE:COV)

Covidien (NYSE COV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/22/2015Q115$1.04$1.11$2.72 billion$2.69 billionViewN/AView Earnings Details
11/5/2014Q414$1.02$1.15$2.69 billion$2.73 billionViewListenView Earnings Details
7/25/2014Q314$1.00$1.04$2.69 billion$2.69 billionViewListenView Earnings Details
4/25/2014Q214$0.95$0.96$2.61 billion$2.60 billionViewListenView Earnings Details
1/24/2014Q114$0.94$1.00$2.61 billion$2.64 billionViewListenView Earnings Details
11/8/2013Q4 2013$0.90$0.91$2.5606 billion$2.56 billionViewN/AView Earnings Details
8/1/2013Q3 2013$0.89$0.85$2.58 billion$2.58 billionViewListenView Earnings Details
4/26/2013Q2 2013$1.09$1.12$3.12 billion$3.1030 billionViewListenView Earnings Details
1/25/2013Q1 2013$1.06$1.10$3.00 billion$3.06 billionViewListenView Earnings Details
11/9/2012Q412$1.00$1.02$2.9809 billion$3.0010 billionViewN/AView Earnings Details
7/26/2012$1.06$1.07ViewN/AView Earnings Details
4/27/2012$1.03$1.05ViewN/AView Earnings Details
1/26/2012$1.03$1.13ViewN/AView Earnings Details
11/15/2011$1.05$1.08ViewN/AView Earnings Details
7/26/2011$0.94$1.01ViewN/AView Earnings Details
4/21/2011$0.89$0.93ViewN/AView Earnings Details
2/1/2011$0.81$0.95ViewN/AView Earnings Details
11/9/2010Q4 2010$0.74$0.84ViewN/AView Earnings Details
7/29/2010Q3 2010$0.80$0.85ViewN/AView Earnings Details
4/21/2010Q2 2010$0.83$0.88ViewN/AView Earnings Details
1/20/2010Q1 2010$0.75$0.86ViewN/AView Earnings Details
11/17/2009Q4 2009$0.70$0.72ViewN/AView Earnings Details
7/30/2009Q3 2009$0.66$0.74ViewN/AView Earnings Details
4/30/2009Q2 2009$0.85$0.69ViewN/AView Earnings Details
1/26/2009Q1 2009$0.70$0.76ViewN/AView Earnings Details
11/17/2008Q4 2008$0.68$0.73ViewN/AView Earnings Details
8/5/2008Q3 2008$0.66$0.73ViewN/AView Earnings Details
5/6/2008Q2 2008$0.58$0.66ViewN/AView Earnings Details
2/7/2008Q1 2008$0.57$0.59ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Covidien (NYSE:COV) Dividend Information

Covidien pays an annual dividend of $0.00 per share, with a dividend yield of 0.00%. COV's most recent quarterly dividend payment was Friday, January 16.
Most Recent Dividend:1/16/2015
Dividend Yield:0.00%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:N/A
Dividend Payments by Quarter for Covidien (NYSE:COV)

Covidien (NYSE:COV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Covidien (NYSE COV) Insider Trading and Institutional Ownership History

Insider Trading History for Covidien (NYSE:COV)

Covidien (NYSE COV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/25/2017Elinor CaplanDirectorSell3,333$0.00$0.00
9/7/2017Jeffrey MandelDirectorSell9,000$2.99$26,910.00
9/6/2017Jeffrey MandelDirectorSell1,000$2.99$2,990.00
2/1/2017Murray MillerDirectorBuy20,000$2.15$43,000.00
2/9/2016Elinor CaplanDirectorBuy4,500$0.80$3,600.00
8/28/2015Elinor CaplanDirectorBuy8,000$0.80$6,400.00
6/16/2015Elinor CaplanDirectorBuy5,000$1.05$5,250.00
12/5/2014Michael SgrignariSVPSell25,795$103.48$2,669,266.60View SEC Filing  
12/3/2014Dennis H ReilleyDirectorSell10,521$101.39$1,066,724.19View SEC Filing  
11/17/2014Richard G Brown JrVPBuy5,300$94.44$500,532.00View SEC Filing  
11/7/2014Robert H BrustDirectorSell4,000$92.03$368,120.00View SEC Filing  
8/27/2014Coleman N Lannum IIIVPBuy3,338$87.23$291,173.74View SEC Filing  
8/26/2014Coleman N Lannum IIIVPBuy1,736$87.46$151,830.56View SEC Filing  
8/19/2014Coleman N Lannum IIIVPBuy1,720$87.82$151,050.40View SEC Filing  
8/18/2014Coleman N Lannum IIIVPBuy4,100$87.58$359,078.00View SEC Filing  
6/16/2014Jose E AlmeidaInsiderSell51,166$92.05$4,709,830.30View SEC Filing  
4/29/2014Brian Douglas KingVPSell15,569$70.11$1,091,542.5937,173View SEC Filing  
3/28/2014Charles DockendorffCFOSell90,730$72.50$6,577,925.00112,131View SEC Filing  
2/28/2014Jose AlmeidaInsiderSell50,000$72.00$3,600,000.00213,750View SEC Filing  
2/13/2014Richard Brown, Jr.VPSell4,000$71.00$284,000.0054,040View SEC Filing  
2/11/2014Brian Douglas KingVPSell17,946$70.00$1,256,220.0037,111View SEC Filing  
2/11/2014Bryan HansonSVPSell32,480$69.97$2,272,625.6026,334View SEC Filing  
1/29/2014Coleman Lannum IIIVPSell13,787$69.23$954,474.017,564View SEC Filing  
1/24/2014Richard Brown, Jr.VPSell4,000$70.00$280,000.0058,040View SEC Filing  
(Data available from 1/1/2013 forward)


Covidien (NYSE COV) News Headlines

Medtronic to Grow on Strong Fundamentals, High Costs a WoeMedtronic to Grow on Strong Fundamentals, High Costs a Woe
finance.yahoo.com - April 5 at 4:07 PM
Reviewing Covidien (COV) and Bio-Rad Laboratories (BIO)Reviewing Covidien (COV) and Bio-Rad Laboratories (BIO)
www.americanbankingnews.com - February 10 at 12:44 PM
Global Contrast Injector Systems Market Expected to Reach $954.62 Million by 2023 - Allied Market ResearchGlobal Contrast Injector Systems Market Expected to Reach $954.62 Million by 2023 - Allied Market Research
www.bizjournals.com - December 14 at 6:12 PM
Top Analyst Upgrades and Downgrades: Freeport-McMoRan, Medtronic, Northrup Grumman, SailPoint, Stitch Fix, Verizon and MoreTop Analyst Upgrades and Downgrades: Freeport-McMoRan, Medtronic, Northrup Grumman, SailPoint, Stitch Fix, Verizon and More
www.msn.com - December 12 at 9:33 AM
Financial Contrast: Covidien (COV) versus The CompetitionFinancial Contrast: Covidien (COV) versus The Competition
www.americanbankingnews.com - December 6 at 3:12 AM
Reviewing Covidien (COV) & Its RivalsReviewing Covidien (COV) & Its Rivals
www.americanbankingnews.com - December 3 at 4:14 PM
Reviewing Covidien (COV) and The CompetitionReviewing Covidien (COV) and The Competition
www.americanbankingnews.com - November 9 at 1:44 PM
TE Connectivity Announces Fourth Quarter and Full Year Results for Fiscal Year ...TE Connectivity Announces Fourth Quarter and Full Year Results for Fiscal Year ...
www.prnewswire.com - November 1 at 6:18 PM
Interventional Neurology Devices Market Report, Size, Share, Analysis 2017 and Forecast to 2023Interventional Neurology Devices Market Report, Size, Share, Analysis 2017 and Forecast to 2023
www.marketwatch.com - October 12 at 11:18 PM
Covalon Announces The Commencement Of Trading On The OTCQX Market In The United StatesCovalon Announces The Commencement Of Trading On The OTCQX Market In The United States
www.thestreet.com - September 18 at 5:25 PM
Global Angioplasty Balloons Market 2017-2027Global Angioplasty Balloons Market 2017-2027
www.marketwatch.com - May 15 at 12:04 PM
Electroencephalography (EEG) Systems - Global Market Outlook (2016-2022)Electroencephalography (EEG) Systems - Global Market Outlook (2016-2022)
www.bizjournals.com - April 27 at 4:55 PM
Global Medical Device Contract Manufacturing Market Forecast 2017-2027Global Medical Device Contract Manufacturing Market Forecast 2017-2027
www.marketwatch.com - April 19 at 12:44 PM
Fitch Revises Cardinal Healths Outlook to Negative Following $6B DealFitch Revises Cardinal Health's Outlook to Negative Following $6B Deal
www.reuters.com - April 18 at 12:16 PM
Company Overview of Nippon Covidien Ltd.Company Overview of Nippon Covidien Ltd.
www.bloomberg.com - March 15 at 9:55 PM
Global Biosimilar Drugs Market - Forecast & Analysis to 2022 - In-depth Analysis at Regional & Country Level - Research and MarketsGlobal Biosimilar Drugs Market - Forecast & Analysis to 2022 - In-depth Analysis at Regional & Country Level - Research and Markets
www.finanznachrichten.de - March 15 at 4:53 PM

SEC Filings

Covidien (NYSE:COV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Covidien (NYSE:COV) Income Statement, Balance Sheet and Cash Flow Statement


Covidien (NYSE COV) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.